Affordable Access

deepdyve-link
Publisher Website

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Authors
  • Guzauskas, Gregory F1
  • Salzberg, Marc2
  • Wang, Bruce Cm1, 3
  • 1 Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.
  • 2 Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA.
  • 3 Elysia Group, LLC, New York, NY 10017, USA.
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Jul 01, 2018
Volume
7
Issue
3
Identifiers
DOI: 10.2217/cns-2018-0010
PMID: 30124334
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years. Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost-effectiveness of TTFields.

Report this publication

Statistics

Seen <100 times